Cytokinetics Inc (CYTK): who owns it and who trades it
As of Nov 16, 2026, CYTK insiders reported 86 open-market sales worth $52M and no purchases in the last 12 months, with 91% of the sale value made under pre-set 10b5-1 plans. The largest seller was Robert I Blum (CEO), with $17.6M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Cytokinetics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and Congress mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CYTK
478 funds and institutions reported CYTK shares worth $13.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 16.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 20.09M | 16.15% | $1.7B | +21% |
| T. Rowe Price Investment Management, Inc. | 18.72M | 15.04% | $1.6B | +7% |
| Wellington Management Group LLP | 6.93M | 5.57% | $591M | -13% |
| Vanguard Portfolio Management LLC | 6.71M | 5.39% | $572M | +15% |
| State Street Corp | 6.49M | 5.22% | $553M | +13% |
| Vanguard Capital Management LLC | 6.12M | 4.92% | $521M | +11% |
| FMR LLC (Fidelity) | 5.03M | 4.04% | $429M | -53% |
| Avoro Capital Advisors LLC | 5.00M | 4.02% | $426M | +50% |
| Bank of America Corp | 4.64M | 3.73% | $395M | +48% |
| Geode Capital Management, LLC | 3.71M | 2.98% | $316M | +15% |
| Rtw Investments, LP | 2.86M | 2.30% | $244M | +5% |
| Polar Capital Holdings Plc | 2.25M | 1.81% | $192M | +36% |
| T. Rowe Price Associates | 1.96M | 1.57% | $167M | +24% |
| Goldman Sachs Group Inc | 1.76M | 1.42% | $150M | -20% |
| Capital Research Global Investors | 1.69M | 1.36% | $144M | +119% |
| Northern Trust Corp | 1.65M | 1.32% | $140M | +14% |
| William Blair Investment Management, LLC | 1.60M | 1.29% | $137M | +47% |
| Integral Health Asset Management, LLC | 1.60M | 1.29% | $136M | No change |
| JPMorgan Chase & Co | 1.59M | 1.28% | $139M | – |
| Point72 Asset Management, L.P. | 1.59M | 1.28% | $135M | +154% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CYTK insiders reported $0 of open-market purchases and $52M of sales. 91% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | B Lynne Parshall | Director | Sale plan | 2,445 | $54.17 | $132K | Form 4 |
| Nov 9, 2026 | B Lynne Parshall | Director | Sale plan | 2,555 | $55.26 | $141K | Form 4 |
| Nov 3, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $62.93 | $220K | Form 4 |
| Nov 2, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $62.81 | $471K | Form 4 |
| Oct 20, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $64.01 | $224K | Form 4 |
| Oct 12, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $62.88 | $472K | Form 4 |
| Oct 6, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $61.38 | $215K | Form 4 |
| Sep 28, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $65.46 | $491K | Form 4 |
| Sep 22, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $68.29 | $239K | Form 4 |
| Sep 15, 2026 | Robert E Landry | Director | Sale plan | 1,000 | $72.13 | $72.1K | Form 4 |
| Sep 15, 2026 | Robert I Blum | CEO | Sale plan | 97,926 | $69.33 | $6.8M | Form 4 |
| Sep 14, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $73.44 | $551K | Form 4 |
| Sep 11, 2026 | Robert E Landry | Director | Sale plan | 1,000 | $74.66 | $74.7K | Form 4 |
| Sep 8, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $75.46 | $264K | Form 4 |
| Sep 1, 2026 | B Lynne Parshall | Director | Sale plan | 5,000 | $71.48 | $357K | Form 4 |
| Aug 31, 2026 | Andrew Callos | Vice president | Sale plan | 10,000 | $70.24 | $702K | Form 4 |
| Aug 31, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $70.24 | $527K | Form 4 |
| Aug 18, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $75.82 | $265K | Form 4 |
| Aug 10, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $76.76 | $576K | Form 4 |
| Jul 30, 2026 | Andrew Callos | Vice president | Sale plan | 14,000 | $79.88 | $1.1M | Form 4 |
| Jul 27, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $80.87 | $607K | Form 4 |
| Jul 21, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $80.59 | $282K | Form 4 |
| Jul 13, 2026 | Robert I Blum | CEO | Sale plan | 10 | $82.02 | $820 | Form 4 |
| Jul 13, 2026 | Robert I Blum | CEO | Sale plan | 7,490 | $82.02 | $614K | Form 4 |
| Jul 7, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $86.62 | $303K | Form 4 |
| Jul 1, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $84.92 | $637K | Form 4 |
| Jul 1, 2026 | Andrew Callos | Vice president | Sale plan | 15,000 | $85.80 | $1.3M | Form 4 |
| Jul 1, 2026 | Sung Lee | CFO | Sale plan | 1,112 | $87.79 | $97.6K | Form 4 |
| Jun 29, 2026 | Sung Lee | CFO | Sale plan | 3,134 | $85.00 | $266K | Form 4 |
| Jun 24, 2026 | Sung Lee | CFO | Sale plan | 38,730 | $82.30 | $3.2M | Form 4 |
| Jun 23, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $79.51 | $278K | Form 4 |
| Jun 15, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $70.46 | $528K | Form 4 |
| Jun 9, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $67.98 | $238K | Form 4 |
| Jun 1, 2026 | Edward M. MD Kaye | Director | Sale plan | 2,933 | $76.09 | $223K | Form 4 |
| Jun 1, 2026 | Andrew Callos | Vice president | Sale plan | 15,000 | $74.08 | $1.1M | Form 4 |
| Jun 1, 2026 | B Lynne Parshall | Director | Sale plan | 5,000 | $74.08 | $370K | Form 4 |
| May 27, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $77.21 | $579K | Form 4 |
| May 19, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $75.69 | $265K | Form 4 |
| May 14, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $77.92 | $584K | Form 4 |
| May 5, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $77.37 | $271K | Form 4 |
| May 5, 2026 | Wendell Wierenga | Director | Sale plan | 4,032 | $75.00 | $302K | Form 4 |
| May 5, 2026 | Sung Lee | CFO | Sale plan | 23,906 | $76.87 | $1.8M | Form 4 |
| May 5, 2026 | John T Henderson | Director | Sale plan | 20,000 | $75.97 | $1.5M | Form 4 |
| May 5, 2026 | Andrew Callos | Vice president | Sale plan | 11,333 | $77.25 | $875K | Form 4 |
| May 1, 2026 | Andrew Callos | Vice president | Sale plan | 15,857 | $65.00 | $1M | Form 4 |
| Apr 30, 2026 | Andrew Callos | Vice president | Sale plan | 15,000 | $63.26 | $949K | Form 4 |
| Apr 29, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $59.62 | $447K | Form 4 |
| Apr 21, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $65.69 | $230K | Form 4 |
| Apr 15, 2026 | Andrew Callos | Vice president | Sale plan | 7,449 | $66.02 | $492K | Form 4 |
| Apr 15, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $65.38 | $490K | Form 4 |
| Apr 7, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 1,000 | $64.75 | $64.8K | Form 4 |
| Apr 7, 2026 | Fady Ibraham Malik | Vice president | Sale plan | 3,500 | $65.21 | $228K | Form 4 |
| Apr 1, 2026 | Robert I Blum | CEO | Sale plan | 7,500 | $66.63 | $500K | Form 4 |
| Mar 31, 2026 | Andrew Callos | Vice president | Sale plan | 3,639 | $65.00 | $237K | Form 4 |
| Mar 18, 2026 | Andrew Callos | Vice president | Sale plan | 1,930 | $62.07 | $120K | Form 4 |
| Mar 17, 2026 | Sung Lee | CFO | Sale | 4,935 | $62.15 | $307K | Form 4 |
| Mar 17, 2026 | Andrew Callos | Vice president | Sale | 5,626 | $62.15 | $350K | Form 4 |
| Mar 17, 2026 | Andrew Callos | Vice president | Sale | 2,916 | $62.15 | $181K | Form 4 |
| Mar 17, 2026 | Fady Ibraham Malik | Vice president | Sale | 4,397 | $62.15 | $273K | Form 4 |
| Mar 17, 2026 | Fady Ibraham Malik | Vice president | Sale | 7,636 | $62.15 | $475K | Form 4 |
| Mar 17, 2026 | Robert I Blum | CEO | Sale | 12,673 | $62.15 | $788K | Form 4 |
| Mar 17, 2026 | Robert I Blum | CEO | Sale | 23,928 | $62.15 | $1.5M | Form 4 |
| Mar 16, 2026 | Andrew Callos | Vice president | Sale plan | 1,709 | $61.03 | $104K | Form 4 |
| Mar 9, 2026 | Andrew Callos | Vice president | Sale | 2,582 | $60.72 | $157K | Form 4 |
| Mar 9, 2026 | Fady Ibraham Malik | Vice president | Sale | 2,907 | $60.72 | $177K | Form 4 |
| Mar 9, 2026 | Robert I Blum | CEO | Sale | 7,931 | $60.72 | $482K | Form 4 |
| Mar 5, 2026 | Andrew Callos | Vice president | Sale plan | 11,000 | $61.88 | $681K | Form 4 |
| Mar 5, 2026 | Andrew Callos | Vice president | Sale plan | 15,000 | $61.87 | $928K | Form 4 |
| Mar 2, 2026 | B Lynne Parshall | Director | Sale plan | 5,000 | $61.21 | $306K | Form 4 |
| Mar 2, 2026 | Andrew Callos | Vice president | Sale plan | 886 | $61.62 | $54.6K | Form 4 |
| Feb 5, 2026 | Andrew Callos | Vice president | Sale plan | 15,000 | $61.93 | $929K | Form 4 |
| Feb 2, 2026 | Andrew Callos | Vice president | Sale plan | 886 | $62.10 | $55K | Form 4 |
| Jan 5, 2026 | Andrew Callos | Vice president | Sale plan | 15,000 | $60.28 | $904K | Form 4 |
| Jan 2, 2026 | Andrew Callos | Vice president | Sale plan | 913 | $62.09 | $56.7K | Form 4 |
| Jan 2, 2026 | Andrew Callos | Vice president | Sale plan | 885 | $63.16 | $55.9K | Form 4 |
| Dec 29, 2025 | Andrew Callos | Vice president | Sale plan | 1,809 | $62.44 | $113K | Form 4 |
| Dec 22, 2025 | Wendell Wierenga | Director | Sale plan | 20,000 | $66.14 | $1.3M | Form 4 |
| Dec 16, 2025 | Fady Ibraham Malik | Vice president | Sale plan | 2,200 | $61.24 | $135K | Form 4 |
| Dec 8, 2025 | Andrew Callos | Vice president | Sale plan | 1,042 | $65.96 | $68.7K | Form 4 |
| Dec 5, 2025 | Andrew Callos | Vice president | Sale plan | 52,486 | $65.95 | $3.5M | Form 4 |
| Dec 2, 2025 | John T Henderson | Director | Sale plan | 8,750 | $63.90 | $559K | Form 4 |
| Dec 2, 2025 | Fady Ibraham Malik | Vice president | Sale plan | 2,200 | $63.89 | $141K | Form 4 |
| Dec 1, 2025 | Edward M. MD Kaye | Director | Sale plan | 28,064 | $66.72 | $1.9M | Form 4 |
| Dec 1, 2025 | Robert Arthur Harrington | Director | Sale plan | 2,150 | $66.80 | $144K | Form 4 |
| Nov 19, 2025 | B Lynne Parshall | Director | Sale plan | 5,000 | $64.73 | $324K | Form 4 |
| Nov 18, 2025 | Fady Ibraham Malik | Vice president | Sale plan | 2,200 | $66.45 | $146K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Robert I Blum | President & CEO, Director | – | $17.6M | Nov 2, 2026 |
| Andrew Callos | EVP, Chief Commercial Officer | – | $16M | Aug 31, 2026 |
| Sung Lee | EVP, Chief Financial Officer | – | $5.7M | Jul 1, 2026 |
| Fady Ibraham Malik | EVP Research & Development | – | $4.9M | Nov 3, 2026 |
| Edward M. MD Kaye | Director | – | $2.1M | Jun 1, 2026 |
| John T Henderson | Director | – | $2.1M | May 5, 2026 |
| B Lynne Parshall | Director | – | $1.6M | Nov 9, 2026 |
| Wendell Wierenga | Director | – | $1.6M | May 5, 2026 |
| Robert E Landry | Director | – | $147K | Sep 15, 2026 |
| Robert Arthur Harrington | Director | – | $144K | Dec 1, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CYTK short interest
High short interest. 12.9% of CYTK shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 9%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17.93M CYTK shares were sold short, 12.9% of the shares outstanding, down 3.7% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 14.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17.93M | 12.90% | -4% | 1.27M | 14.2 |
| Oct 15, 2026 | 18.63M | 13.40% | -4% | 2.14M | 8.7 |
| Sep 30, 2026 | 19.33M | 13.91% | +11% | 2.31M | 8.4 |
| Sep 15, 2026 | 17.48M | 12.57% | +0% | 1.66M | 10.6 |
| Aug 31, 2026 | 17.44M | 12.55% | +7% | 1.79M | 9.7 |
| Aug 14, 2026 | 16.32M | 11.74% | +7% | 2.12M | 7.7 |
| Jul 31, 2026 | 15.30M | 12.30% | -10% | 1.59M | 9.6 |
| Jul 15, 2026 | 17.05M | 13.70% | -3% | 1.90M | 9.0 |
| Jun 30, 2026 | 17.57M | 14.12% | +19% | 3.34M | 5.3 |
| Jun 15, 2026 | 14.77M | 11.87% | -5% | 1.59M | 9.3 |
| May 29, 2026 | 15.50M | 12.46% | -6% | 1.81M | 8.6 |
| May 15, 2026 | 16.46M | 13.23% | +4% | 4.86M | 3.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded CYTK
Since Nov 17, 2024, 2 members of Congress reported 4 purchases and 1 sale of CYTK. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Sep 29, 2026, reported Oct 12, 2026.
Purchases 4Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Oct 12, 2026 | Report |
| Jun 30, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jul 2, 2026 | Report |
| Oct 9, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Nov 18, 2025 | Report |
| Jun 17, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 11, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Cytokinetics company events
Cytokinetics filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 28, 2026AnnouncementCytokinetics, Incorporated issued a press release announcing its presentation of the full results of ACACIA-HCM at the European Society of Cardiology (ESC) Congress 2026 and published in the New England Journal of Medicine. Filing
- Aug 13, 2026AnnouncementCytokinetics, Incorporated filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory judgment that the Company does not infringe U.S. Patent No. 12,616,697 and that the claims of the… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- May 27, 2026VoteReported shareholder vote results. Filing
- May 8, 2026AnnouncementCytokinetics, Incorporated entered into an underwriting agreement with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein, relating to the public offering, issuance and sale of 9,859,155… Filing
- May 5, 2026AnnouncementCytokinetics, Incorporated released its current corporate presentation, which is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 8.01. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Feb 17, 2026AnnouncementCytokinetics, Incorporated today announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy in adult patients. Filing
- Dec 19, 2025AnnouncementCytokinetics, Incorporated announced that the U.S. Food and Drug Administration has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Filing
- Dec 12, 2025AnnouncementCytokinetics, Incorporated announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cytokinetics financials
Famous investors that hold CYTK
4 of the 50 well-known investors we track reported holding CYTK in their latest 13F filing. The largest position is Ken Fisher's, worth $54M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 818,832 | $54M | 0.0% | +10% |
| Israel Englander · Millennium Management | Q3 2026 | 277,135 | $18.3M | 0.0% | +153% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 204,231 | $13.5M | 0.0% | -68% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 9,770 | $644K | 0.0% | -89% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named CYTK in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 7.7% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 7.7% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.1% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.1% |
Questions about Cytokinetics Inc (CYTK) stock
Who owns the most CYTK stock?
The largest reported owner of Cytokinetics Inc (CYTK) is BlackRock, Inc., with 16.1% of the company. In total, 478 funds and institutions reported holding CYTK at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CYTK insiders buying or selling?
In the last 12 months, CYTK insiders reported no open-market purchases and 86 sales worth $52M. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in CYTK?
As of Oct 30, 2026, 17.93M CYTK shares were sold short, 12.9% of the shares outstanding, down 3.7% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 14.2 trading days (days to cover). See the history.
Have members of Congress traded CYTK?
Yes. 2 members of Congress reported 4 purchases and 1 sale of CYTK since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.
Which famous investors hold CYTK?
4 of the 50 well-known investors we track reported CYTK in their latest 13F filing, including Ken Fisher, Israel Englander, Ken Griffin. The largest position is worth $54M. See all holders.
Executive pay
Cytokinetics's chief executive was paid a total of $11.9M for the year ended Dec 31, 2025, down 17% from $14.4M the year before. In the last 12 months, Cytokinetics's executives and directors bought no stock on the open market and sold $52M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.